These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 16966688

  • 1. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG, Oblimersen Melanoma Study Group.
    J Clin Oncol; 2006 Oct 10; 24(29):4738-45. PubMed ID: 16966688
    [Abstract] [Full Text] [Related]

  • 2. Oblimersen in the treatment of metastatic melanoma.
    Tarhini AA, Kirkwood JM.
    Future Oncol; 2007 Jun 10; 3(3):263-71. PubMed ID: 17547520
    [Abstract] [Full Text] [Related]

  • 3. Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.
    Bedikian AY, Garbe C, Conry R, Lebbe C, Grob JJ, Genasense Melanoma Study Group.
    Melanoma Res; 2014 Jun 10; 24(3):237-43. PubMed ID: 24667300
    [Abstract] [Full Text] [Related]

  • 4. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
    Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, Stein CA, Itri LM, Suciu S, Eggermont AM.
    Eur J Cancer; 2009 Jul 10; 45(10):1807-14. PubMed ID: 19419855
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 6. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD.
    Oncology (Williston Park); 2004 Nov 20; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [Abstract] [Full Text] [Related]

  • 7. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007 Nov 20; 8(5):321-34. PubMed ID: 17767397
    [Abstract] [Full Text] [Related]

  • 8. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
    Agarwala SS, Neuberg D, Park Y, Kirkwood JM.
    Cancer; 2004 Apr 15; 100(8):1692-8. PubMed ID: 15073858
    [Abstract] [Full Text] [Related]

  • 9. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y.
    J Clin Oncol; 2004 Mar 15; 22(6):1118-25. PubMed ID: 15020614
    [Abstract] [Full Text] [Related]

  • 10. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
    Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC.
    J Clin Oncol; 2005 May 20; 23(15):3404-11. PubMed ID: 15824414
    [Abstract] [Full Text] [Related]

  • 11. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
    McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E.
    J Clin Oncol; 2008 May 01; 26(13):2178-85. PubMed ID: 18445842
    [Abstract] [Full Text] [Related]

  • 12. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
    Herbst RS, Frankel SR.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
    [Abstract] [Full Text] [Related]

  • 13. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer S, Middleton MR.
    Lancet Oncol; 2013 Jul 15; 14(8):733-40. PubMed ID: 23735514
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC.
    Chemotherapy; 2009 Jul 15; 55(4):221-7. PubMed ID: 19451711
    [Abstract] [Full Text] [Related]

  • 15. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E.
    Clin Cancer Res; 2005 May 15; 11(10):3854-61. PubMed ID: 15897586
    [Abstract] [Full Text] [Related]

  • 16. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
    Busch C, Geisler J, Lillehaug JR, Lønning PE.
    Eur J Cancer; 2010 Jul 15; 46(11):2127-33. PubMed ID: 20541396
    [Abstract] [Full Text] [Related]

  • 17. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
    Tan EH, Ang PT.
    Singapore Med J; 1996 Apr 15; 37(2):165-7. PubMed ID: 8942255
    [Abstract] [Full Text] [Related]

  • 18. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
    Ott PA, Chang J, Madden K, Kannan R, Muren C, Escano C, Cheng X, Shao Y, Mendoza S, Gandhi A, Liebes L, Pavlick AC.
    Cancer Chemother Pharmacol; 2013 Jan 15; 71(1):183-91. PubMed ID: 23064957
    [Abstract] [Full Text] [Related]

  • 19. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Rudolf Z, Strojan P.
    Neoplasma; 1996 Jan 15; 43(2):93-7. PubMed ID: 8843969
    [Abstract] [Full Text] [Related]

  • 20. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
    Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E.
    Cancer; 2010 Aug 01; 116(15):3683-91. PubMed ID: 20564083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.